

Goodbody Asset Management

Goodbody Global Smaller Companies Fund

- Macro environment impacting business' growth outlooks
- Dechra Pharmaceutical – a new addition to the Fund

Risk rating 1 2 3 4 5 **6** 7

Fund performance

Sector allocation and stock selection contributed to the Fund's underperformance in May. The Fund has no holdings in the Energy sector, which was a notable outperformer during the month. Cognex had its results early in the month and beat estimates for the quarter, but management commentary guided for slowing growth and automation project delays due to supply chain challenges and staffing shortages. Belimo, a Swiss company in the HVAC industry, fell 21% on rising raw material cost intensity. During the month we initiated a position in Dechra Pharmaceutical, a UK based specialist in veterinary pharmaceuticals, focused on chronic illness and critical care.

Fund price since inception



	1 MTH	3 MTH	YTD	1 YR	3 YR p.a.	2021	2020	2019	2018	2017	Since inception
Fund	-6.0%	-7.5%	-21.9%	-5.2%	13.2%	38.3%	13.6%	38.6%	-7.4%	17.8%	97.2%
Benchmark	-1.8%	-2.6%	-8.6%	1.4%	12.1%	25.8%	6.8%	30.0%	-8.9%	8.4%	72.3%

Source: Goodbody, Bloomberg, Benchmark in Euro terms

Performance of Goodbody Global Smaller Companies Fund

The **Goodbody Global Smaller Companies Fund** is an actively managed, concentrated global equity fund that offers an investment in a diversified portfolio of 40 small/mid sized growth companies. The fund aims to outperform the MSCI World Small/Mid cap index in Euro terms over the medium to long-term.

Key information

Fund launch date	28 October 2016
Fund type	UCITS
Base currency	€
Pricing/Dealing	Daily
Share class	B
ISIN	IE00BYNJZ92
Month end NAV (€)	19.72
Investment management fee	0.50%
Number of holdings	34
Top 10 as % of the fund	38%
Active share*	98%

Geographic mix as at 31 May 2022



North America	56%
Europe (ex. UK)	21%
UK	16%
Asia Pacific (ex. Japan)	4%
Japan	2%

Source: Goodbody

Why consider the Goodbody Global Smaller Companies Fund?

1. Return enhancement potential

Global small/mid cap equities have historically offered a compelling risk/reward opportunity compared to their large cap counterparts.

2. Diversification benefits

The fund invests in a segment of the equity market that is frequently overlooked and neglected by other investors.

3. Proven smaller company expertise

Our investment team has successfully delivered strong performance in the small/mid cap segment of the equity market over the last 15 years.

Warning: Past performance is not a reliable guide to future performance.

Sector split as at 31 May 2022

Industrials	32%
Technology	24%
Consumer discretionary	18%
Healthcare	15%
Materials	7%
Financials	3%
Energy	0%
Consumer staples	0%
Real Estate	0%
Telecoms	0%
Utilities	0%

Source: Goodbody

Top 10 holdings as at 31 May 2022

Ulta Beauty	4.3%
ICON	4.3%
Manhattan Associates	4.1%
Cooper Companies	3.9%
Avery Dennison	3.7%
IDEX Corp	3.7%
Teleperformance	3.6%
Tractor Supply	3.4%
Paylocity	3.4%
Huntington Bancshares	3.3%

Source: Goodbody

Market commentary

May was another volatile month for equity and bond markets with inflation continuing to dominate the narrative. The MSCI World Index finished the month 1.5% lower in euro terms. Having touched on 3.2% at the beginning of May, the US 10 year yield ended the month close to 2.8%. The German 10 year yield rose by c.20bps, ending the month above 1.1%. Meanwhile, Italian government bonds remained under pressure with the Italian 10 year yield reaching 3.1%. Central banks maintained their respective hawkish tone. As expected, the Fed delivered on a 50bps interest rate hike and signalled that interest rates may have to move above the “neutral rate” in order to bring inflation back to target. US headline inflation came in above expectations but fell slightly from the previous month to 8.3%. In Europe, ECB President Christine Lagarde all but confirmed the market expectations that it would deliver a 25bps interest rate hike in July, its first hike since 2011. During the month EUR/USD broke below \$1.04, its lowest level since 2016, before somewhat recovering into month end.

Prospectus and Key Investor Information

A copy of the English version of the Prospectus of the Fund and the Key Investor Information (KIID) document relating to the Fund is available [here](#) and may also be obtained [here](#) to view the Prospectus and [here](#) to view the KIID. Where required under national rules, the KIID document will also be available in the local language of the relevant EEA Member State.

Summary of Investor Rights

A summary of investor rights associated with an investment in the Fund shall be available in English [here](#).

Termination of Marketing Arrangements

A decision may be taken at any time to terminate the arrangements made for the marketing of the Fund in any EEA Member State in which it is currently marketed. In such circumstances, Shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the Fund free of any charges or deductions for at least 30 working days from the date of such notification.

Warning: The value of your investment may go down as well as up. This fund may be affected by changes in currency exchange rates. If you invest in this fund you may lose some or all of the money you invest.

*Active Share is a measure of the Fund's overlap with the benchmark. An active share of 100% indicates that the Fund has no holdings in common with the benchmark and active share of 0% indicates a Fund that tracks the benchmark.

This publication has been approved by Goodbody Stockbrokers UC. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

The Fund is a sub-fund of Goodbody Funds ICAV, which is an undertaking for Collective Investment in Transferable Securities (UCITS) with limited liability between sub-funds. Investors should read the Prospective Supplement and Key Investor Information document for the Fund, as well as the Information Memorandum prior to making a decision to invest, and for full information on the Fund including fees, risks and conflicts of interest.

This document is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this publication constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you.

Registered Office: Ballsbridge Park, Ballsbridge Dublin 4, Ireland. T: +353 1 667 0400. Registered in Ireland No. 54223.

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland. In the UK, Goodbody is also subject to regulation by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a member of the group of companies headed by AIB Group plc. 000895_0622

Contact us today

Goodbody Asset Management, 2 Ballsbridge Park, Ballsbridge, Dublin 4
T +353 1 641 9470 E assetmanagement@goodbody.ie W www.goodbody.ie/assetmanagement